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ADCY5 mutations are another cause of
benign hereditary chorea
ABSTRACT
Objective: To determine the contribution of ADCY5mutations in cases with genetically undefined
benign hereditary chorea (BHC).
Methods:We studied 18 unrelated cases with BHC (7 familial, 11 sporadic) who were negative for
NKX2-1mutations. The diagnosis of BHC was based on the presence of a childhood-onset move-
ment disorder, predominantly characterized by chorea and no other major neurologic features.
ADCY5 analysis was performed by whole-exome sequencing or Sanger sequencing. ADCY5 and
NKX2-1 expression during brain development and in the adult human brain was assessed using
microarray analysis of postmortem brain tissue.
Results: The c.1252C.T; p.R418W mutation was identified in 2 cases (1 familial, 1 sporadic).
The familial case inherited the mutation from the affected father, who had a much milder presen-
tation, likely due to low-grade somatic mosaicism. The mutation was de novo in the sporadic case.
The clinical presentation of these cases featured nonparoxysmal generalized chorea, as well as
dystonia in the most severely affected, but no facial myokymia. We observed significant progres-
sion of symptoms in ADCY5 mutation carriers, in contrast to BHC secondary to NKX2-1 muta-
tions. The difference in the clinical course is mirrored by the brain expression data, showing
increasing ADCY5 expression in the striatum during brain development, whereas NKX2-1 shows
an opposite trend.
Conclusions: Our study identifies mutations in ADCY5, the gene previously linked to familial
dyskinesia with facial myokymia, as a cause of familial and sporadic BHC. ADCY5 genetic anal-
ysis should be performed in cases with a benign choreiform movement disorder even in the
absence of facial myokymia. Neurology® 2015;85:1–9
GLOSSARY
ADCY5 5 adenylate cyclase 5 gene; BHC 5 benign hereditary chorea; FDFM 5 familial dyskinesia with facial myokymia;
mRNA 5 messenger RNA; OMIM 5 Online Mendelian Inheritance in Man; WES 5 whole-exome sequencing.
Benign hereditary chorea (BHC) (OMIM 118700) is a rare and poorly delineated syndrome,
clinically characterized by onset of symptoms in infancy or early childhood, relatively little clin-
ical progression, and absence of other major neurologic deficits, in particular prominent cogni-
tive decline.1,2
Mutations in the NKX2-1 gene (OMIM 600635) were identified in 2002 as a major cause of
familial and sporadic BHC.3,4 However, a number of families with BHC do not carry mutations
in NKX2-1, suggesting that other genes may be responsible for this syndrome.5–8
Familial dyskinesia with facial myokymia (FDFM) (OMIM 606703) was first described by
Fernandez et al.9 in 2001. They reported a 5-generation kindred with 18 members affected with
an autosomal dominant movement disorder, mainly characterized by childhood or early adolescent
onset of hyperkinetic movements and perioral and periorbital myokymia. The disease locus was
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subsequently mapped to chromosome 3p21-
3q21,10 and recently a missense variant in the
adenylate cyclase 5 gene (ADCY5; OMIM
600293) was identified by next-generation
sequencing as the causative mutation.11
Of note, before the identification of facial
myokymia as one of the core features, individ-
uals from the original FDFM kindred had been
described as affected with familial essential
(“benign”) chorea.12 Given the phenotypic
overlap between FDFM and BHC, we won-
dered whether ADCY5 mutations could be de-
tected in cases clinically diagnosed with BHC
but lacking mutations in NKX2-1. We there-
fore performed a comprehensive mutational
analysis of ADCY5 in a cohort of NKX2-1–
negative cases with a BHC phenotype.
METHODS Standard protocol approvals, registrations,
and patient consents. The study was approved by the UCL
ethics committee (UCLH project 06/N076), and written
informed consent was obtained from all participants.
Patients. All cases included in this study were evaluated in the
Movement Disorder Center of the National Hospital for Neurol-
ogy and Neurosurgery, Queen Square, London.
We studied 18 consecutive unrelated cases, including 7 with
an autosomal dominant family history and 11 sporadic. All par-
ticipants in the study were assessed by neurologists with signifi-
cant expertise in movement disorders (N.Q. and K.P.B.). BHC
was clinically diagnosed based on the presence of a movement dis-
order, with onset before the age of 20 years, predominantly char-
acterized by chorea in the absence of other major neurologic
features (i.e., cognitive decline, ataxia, spasticity, or peripheral
neuropathy). Medical history was negative for toxin exposure
and drugs known to cause chorea.
Basic diagnostic evaluations, including MRI of the brain,
CSF analysis, acanthocytes, antistreptolysin titer, copper, cerulo-
plasmin, and a-fetoprotein, were unremarkable. All cases were
negative for mutations in the NKX2-1 gene and the Huntington
disease triplet repeat expansion. DRPLA, SCA17, and HDL2
expansions were excluded in familial cases. SGCEmutations were
excluded when myoclonus-dystonia was suspected due to the
presence of dystonic features.
Genetic analysis. After informed consent was given, DNA was ex-
tracted from peripheral lymphocytes following a standard protocol.
DNA of patients was analyzed either by whole-exome sequencing
(WES) or by direct Sanger sequencing of the 21 coding exons and
flanking intronic regions of ADCY5 (RefSeq accession number
NM_183357). WES and Sanger sequencing methods are detailed
in the supplementary methods (appendix e-1 on the Neurology®
Web site at Neurology.org). Variants identified by WES were
confirmed by Sanger sequencing. Segregation analysis was
performed in parents and other relatives in mutation-positive cases.
Expression profiling of ADCY5 and NKX2-1 in brain
tissue. Regional distribution of ADCY5 and NKX2-1 messenger
RNA (mRNA) expression in the normal adult human brain was
determined using microarray analysis of human postmortem
brain tissue from the UK Human Brain Expression Consortium
as previously described.13 This dataset is based on exon array
profiling of 1,231 samples from 10 brain areas originating from
134 control individuals. ADCY5 and NKX2-1 mRNA expression
changes during the course of human brain development were
assessed by accessing the data available through the Human Brain
Transcriptome database.14,15
RESULTS Identification of ADCY5 mutations. Analysis
by WES or Sanger sequencing of the ADCY5 coding
sequence revealed 4 different heterozygous mutations.
The pathogenic c.1252C.T; p.R418W variant
was identified in 2 unrelated cases. This amino acid
change has been previously reported in association with
FDFM,16 is absent in all publicly available datasets of
population controls (dbSNP, 1000 Genomes project,
NHLBI exome variant server and Exome Aggregation
Consortium), and is consistently predicted pathogenic
by in silico prediction tools (PolyPhen-2, SIFT, and
MutationTaster).
Another novel missense variant (c.2117C.T;
p.A706V) was identified in the index case of a pedi-
gree with autosomal dominant BHC. The mutation
was predicted benign and tolerated respectively by
PolyPhen-2 and SIFT, but disease-causing by Muta-
tionTaster. Segregation analysis in the family showed
that the mutation was absent in the affected mother
and had been inherited from the unaffected father,
ruling out any pathogenic relevance.
Finally, a variant in the 59 untranslated region
(c.1-5G.C) together with the missense variant
c.29C.T; p.P10L (rs143905423) was detected in a
sporadic case of African ancestry (unknown phase of
the 2 mutations). Both variants are reported with
a minor allele frequency $1% in control individuals
of African ancestry as reported by the Exome Aggre-
gation Consortium, suggesting that both variants are
likely to be neutral.
Clinical presentations of cases with pathogenic ADCY5
mutations. Clinical information of the patients with
pathogenic ADCY5mutations identified in this study
and of those previously reported in the literature is
summarized in the table.
Family 1. The clinical description of this pedigree has
been previously reported.17 The index case is a 36-year-
old British man (subject III-1; figure 1A). His birth and
early development throughout infancy were normal.
Around age 1, he progressively developed brief choreic
movements at rest, affecting the face and the 4 limbs
(video 1, segment 1A). Movements were markedly exac-
erbated by excitement, stress, or tiredness. Around the
age of 18, he also developed painful spasms of the 4
limbs, particularly frequent and severe upon awakening.
Symptoms progressed over the years and clinical exam-
ination at the age of 28 (video 1, segment 1B) revealed
dysarthric speech and severe abnormal involuntary
movements comprising generalized chorea with facial
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Table Clinical features of cases with pathogenic ADCY5 mutations described in this study and reported in the literature
This study Literature
Family 1/subject II-1 Family 1/subject III-1
Family 2/subject II-
1 Original FDFM pedigree9 Subject ID116
Subject
UW116 Subject II-120 Subject III-120
Ethnic origin UK-Caucasian UK-Caucasian UK-Pakistani US-Caucasian US-Caucasian US-
Caucasian
France France
Age at onset 1 y 1 y 2 y Early childhood to late
adolescence
2 y 5 y 6 mo 4 y
Age at examination, y 64 36 22 Range 7–52 15 18 39 15
Mutation c.1252C.T;
p.R418W (low-level
mosaicism)
c.1252C.T;
p.R418W
c.1252C.T;
p.R418W
c.2176G.A; p.A726T c.1252C.T; p.R418W c.1252C.T;
p.R418W
c.208811G.A; p? c.208811G.A; p?
Symptoms at onset Chorea Chorea Chorea and lower
limb dystonia
Paroxysmal chorea Hypotonia and paroxysmal
chorea
Chorea Chorea and lower limb
dystonia
Falls while walking
Developmental
milestones
Normal Normal Delayed Normal Delayed Normal Normal Normal
Dysarthria No Yes Yes No Yes No No No
Facial dyskinesias Few facial twitches Chorea Chorea Chorea, eyelid and perioral
twitches in some members
Perioral and periorbital
dyskinesias
Few facial
twitches
Chorea Chorea
EMG No myokymia No myokymia NA Proven myokymia only in
some members
NA NA NA NA
Chorea Yes, mild Yes, severe and
worsened by action
and anxiety
Yes, severe and
worsened by action
and anxiety
Yes, mild to moderate and
worsened by stress
Paroxysmal chorea, worsened by
anxiety
Yes Yes, mild Yes, moderate
Dystonia No Yes Yes Yes, only in some members Yes Yes Yes Yes
Other features Gaze impersistence,
difficulty initiating
saccades
Gaze impersistence,
difficulty initiating
saccades
Gaze impersistence Head tremor and epileptic
seizures in some members
Intermittent tremors, myoclonic
jerks, hyperreflexia and limb
hypertonia
No Enhanced tendon reflexes
and bilateral extensor
plantar reflexes
Hypotonia,
pyramidal signs
Paroxysmal events Ballistic episodes and
spasms upon
awakening
Ballistic episodes and
spasms upon
awakening
Ballistic episodes
and spasms at night
Dyskinetic episodes
triggered by anxiety/stress
in some members
Myoclonic jerks and ballistic
movements arising from sleep
stages N2 and N3
No No No
Gait Mild difficulty on
tandem walking
Abnormal due to lower
limb choreo-dystonia
Abnormal due to
lower limb choreo-
dystonia
Normal Severely affected with
progressive deterioration
Normal Unsteady gait Normal
Extraneural involvement
(cardiac, respiratory, or
thyroid)
No No No 5 subjects died of
congestive heart failure at
a relatively young age
No No No No
Abbreviations: FDFM 5 familial dyskinesia with facial myokymia; NA 5 not available.
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grimacing and marked dystonic elements. Both chorea
and dystonia were present at rest, but action significantly
exacerbated movements in the limbs. Eye movements
were abnormal with gaze impersistence and use of head
thrust to initiate saccades. Gait was unsteady with both
choreic and dystonic features, but cerebellar testing was
normal. He never displayed facial myokymia and
EMG of periorbital and perioral regions failed to show
either myokymia or other signs of motor neuron
hyperexcitability. Over the years, different medications
were tried without major improvements, including tri-
hexyphenidyl, tetrabenazine, baclofen, levodopa, and
clonazepam. He is currently on a combination of tri-
hexyphenidyl (3 mg/d) and tetrabenazine (75 mg/d),
which he finds helpful in reducing the intensity and
frequency of the spasms.
His 64-year-old father (subject II-1; figure 1A)
also developed involuntary movements in the first
year of life. His involuntary movements mainly con-
sisted of generalized chorea, with no dystonic postur-
ing and overall he has always been much less affected
than the son (video 1, segments 1A and 2).
Besides chorea, on examination, he had marked
ocular and motor impersistence and tandem walking
difficulties. Cerebellar testing was otherwise normal.
At the last follow-up, when he was 61, occasional
twitches were observed in the periorbital areas (video 1,
segment 2), but an EMG performed on the same
day did not show myokymia. A low dose of tetraben-
azine was tried but was not tolerated because of the
development of depression. He is currently taking tri-
hexyphenidyl (7.5 mg/d), with satisfactory control of
Figure 1 Pedigree and genetic results of families 1 (A) and 2 (B) with ADCY5 pathogenic mutations
Affected individuals in the pedigree are indicated by filled symbols. On the left is the visual output of the whole-exome sequencing data and Sanger sequencing
results in the 3 affected individuals carrying the c.1252C.T; p.R418Wmutation. In the top section of each box, the read depth of the exonic portion ofADCY5
involved by the mutation is shown. In the bottom part of each box, samples of the reads carrying the mismatching allele are displayed. The mutant T replacing a
C is highlighted in red. Sanger sequencing failed to show themutation in individual II-1 of family 1. Of note, whole-exome sequencing showed that approximately
8% of reads (9/110) carried the mutated allele in individual II-1 of family 1, indicating parental low-level somatic mosaicism. M 5 mutated; WT 5 wild-type.
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the dyskinesias. Higher doses were not tolerated
because of the occurrence of cognitive difficulties.
There was no history of movement disorders in
other family members, including both paternal
grandparents of the index case.
The heterozygous ADCY5 c.1252C.T; p.R418W
mutation was found by WES and confirmed by direct
sequencing in subject III-1. No other possibly patho-
genic variants in genes linked to chorea or other move-
ment disorders were observed.
Sanger sequencing unexpectedly failed to detect
the mutation in the affected father (figure 1A). Mosa-
icism has been previously reported in patients with
mild presentation of mendelian disorders.18 We
therefore suspected that Sanger sequencing might
have missed the mutation in the father because of
low-grade somatic mosaicism.
Because next-generation sequencing has been
shown to be a more sensitive method to detect this
type of mutation,18,19 WES was performed also in
subject II-1.
Of note, this revealed the presence of the mutated
allele in 9 of 110 sequence reads (approximately 8%
vs 40% in his son; figure 1A), demonstrating the
presence of low-level somatic mosaicism. This sug-
gests that possibly the mutation arose in the father
during early stages of embryogenesis. The unaffected
mother and sister of the index case were wild-type by
Sanger sequencing analysis.
Family 2. This is a 22-year-old man of Pakistani
ethnicity (subject II-1; figure 1B). He is the son of
a consanguineous marriage (parents are first-degree
cousins) and he is the first of 4 siblings. He is the
only affected member in the family. He had delayed
motor milestones with walking at approximately 20
months. Since then, his gait has always been abnor-
mal, being mainly characterized by arching of the
trunk, walking on tiptoes, and inversion of both feet.
Around the age of 2, he developed constant involun-
tary movements involving all 4 limbs and trunk,
which became progressively more evident over the
years. Movements were largely exacerbated by stress
and anxiety. Around the age of 10, he developed “fits”
of violent hyperkinetic movements and painful
spasms of all 4 limbs, mainly occurring at night. A
polysomnographic study performed to investigate
their nature excluded any epileptic activity and
showed that the attacks occurred when the patient
was fully awake.
On examination (video 2), he had moderate gen-
eralized chorea at rest and intermittent distal dystonic
posturing in the 4 limbs. The hyperkinetic move-
ments were dramatically increased by action. Gait
was unsteady, but cerebellar testing was otherwise
normal. Cranial nerve examination showed ocular
impersistence, and frequent facial choreic movements
were also observed. The patient declined an EMG of
the facial muscles. He is currently taking trihexyphe-
nidyl (30 mg/d) and tetrabenazine (50 mg/d), which
partially reduced the intensity of the dyskinesias and
the frequency of the spasms.
WES and subsequent Sanger sequencing analysis
showed the presence in the affected case of the
ADCY5 c.1252C.T; p.R418W change in the heter-
ozygous state (figure 1B). The mutation had likely
occurred de novo, as Sanger sequencing showed its
absence in both healthy parents and in the 3 unaf-
fected siblings. Mutations in other genes associated
with chorea or other movement disorders were
excluded.
Brain expression data. To investigate the differences in
the phenotype and clinical course between BHC due
to ADCY5 and NKX2-1 mutations, we analyzed and
compared expression of the 2 genes across multiple
brain regions and during the course of development.
Consistent with the observed phenotype, mainly
characterized by chorea and dystonia with preserved
cognition and no other major neurologic features, both
ADCY5 and NKX2-1 mRNA expression profiling in
10 brain regions showed the highest expression in the
putamen relative to other brain regions (figure 2A).
When comparing ADCY5 with NKX2-1 expression,
we observed that ADCY5 has a much higher expression
in adult striatum. Furthermore, longitudinal analysis of
mRNA expression during brain development showed
opposite trends for ADCY5 and NKX2-1, with
ADCY5 expression progressively increasing in the stri-
atum from 50 to 500 days postconceptualization and
NKX2-1 progressively decreasing (figure 2D).
DISCUSSION Recently, a gain-of-function heterozygous
missense mutation in ADCY5 (c.2176G.A; p.A726T)
was recognized as the genetic cause in the original FDFM
pedigree.11 The phenotype of the affected members of
this family consisted of hyperkinetic movements starting
from early childhood to late adolescence. A distinctive
feature of this disorder was the presence of prominent
periorbital and perioral facial myokymia.9
After the identification of ADCY5 as the responsi-
ble gene in the original FDFM pedigree, the same
group described a second pathogenic missense variant
in ADCY5 (c.1252C.T; p.R418W), which occurred
de novo in 2 unrelated individuals with a sporadic
complex hyperkinetic movement disorder.16 The phe-
notype of these cases shared some features with the
original FDFM pedigree, but it was more severe and
further encompassed delayed motor milestones, axial
hypotonia, and progressive gait difficulties in one case.
More recently, a splice-site mutation in ADCY5 was
identified in a family with autosomal dominant early-
onset chorea, dystonia, and pyramidal signs.20
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We report here the results of the ADCY5 muta-
tional analysis in a cohort of NKX2-1–negative spo-
radic and familial cases with a BHC-like presentation.
These cases had previously been extensively
investigated for genetic and acquired causes of chorea,
without reaching a conclusive diagnosis.
We identified 3 cases from 2 unrelated pedigrees
bearing the same pathogenic change c.1252C.T;
Figure 2 Graphical summary of brain expression data
(A, B) Boxplots of ADCY5 and NKX2-1 messenger RNA (mRNA) expression levels in 10 adult brain regions. The expression levels are based on exon array
experiments and are plotted on a log2 scale (y-axis). This plot shows significant variation in ADCY5 and NKX2-1 transcript expression across the 10 CNS
regions analyzed: putamen (PUTM), frontal cortex (FCTX), temporal cortex (TCTX), occipital cortex (OCTX), hippocampus (HIPP), substantia nigra (SNIG),
medulla (specifically inferior olivary nucleus, MEDU), intralobular white matter (WHMT), thalamus (THAL), and cerebellar cortex (CRBL).ADCY5 andNKX2-1mRNA
expression is higher in the putamen than in all other brain regions andADCY5 expression in the putamen is significantly higher thanNKX2-1. (C, D) Graphs to show
ADCY5 and NKX2-1 longitudinal mRNA expression in 6 brain regions during the course of human brain development. The expression levels are based on exon
array experiments and are plotted on a log2 scale (y-axis). The brain regions analyzed are the striatum (STR), amygdala (AMY), neocortex (NCX), hippocampus (HIP),
mediodorsal nucleus of the thalamus (MD), and cerebellar cortex (CBC). The plots show increasing expression of ADCY5mRNA during human brain development,
particularly in the striatum, from 50 to 500 days postconceptualization and an opposite trend for NKX2-1.
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p.R418W. The clinical phenotype of these cases pre-
dominantly featured generalized chorea, although
with significant intra- and interfamilial phenotypic
variability.
As previously observed in other cases with the
ADCY5 p.R418W mutation, 2 of the 3 subjects with
the mutation (individual III-1 from family 1 and
individual II-1 from family 2) presented with severe
choreo-dystonic dyskinesias, which were significantly
more disabling than those of individuals carrying the
p.A726T mutation from the original FDFM
pedigree.
Subject II-1 from family 1 had conversely a milder
presentation, with little functional impact from the
dyskinesias. Furthermore, he had isolated chorea
and no dystonic features. Of note, this milder presen-
tation was reflected by the WES data, showing in the
latter case a significantly reduced number of reads car-
rying the mutated allele. This suggests low-level
somatic mosaicism as the likely explanation for the
mitigated phenotype.
In some of the previously described cases with
ADCY5 mutations, dyskinesias were reported as par-
oxysmal in the initial phase of the disease.9,16 Con-
versely, we show that dyskinesias were not
paroxysmal, but constantly present from the onset of
symptoms in the 3 cases we report, albeit markedly
influenced by emotional states and action. It is of inter-
est that all 3 cases developed episodes of violent ballistic
movements and spasms later during the disease course.
The episodes were particularly frequent at night or
upon awakening. Similar episodes were also reported
by Chen et al.16 in individual ID1 (carrier of the
p.R418Wmutation), suggesting that this may be a spe-
cific feature of the ADCY5-related movement disorder.
Facial myokymia has been suggested to be a dis-
tinctive feature of ADCY5-related disorder. However,
an EMG study of the facial muscles performed in
both affected subjects from family 1 (both presenting
facial involuntary movements) did not show myoky-
mia or other signs of motor neuron hyperexcitability.
Although the subject from family 2 refused to
undergo EMG, his facial hyperkinesias were clinically
deemed to be choreiform in nature (video 2). This
indicates that patients with ADCY5 mutations may
present facial choreiform movements in the absence
of myokymia. Consistent with this, facial myokymia
was neither described in affected members from the
original FDFM kindred nor recognized as a promi-
nent feature in the other ADCY5 mutation carriers
who were subsequently reported (table).
Even though the clinical presentation of patients
with ADCY5 mutations is consistent with the clinical
definition of BHC, some clinical clues may help to
recognize and differentiate ADCY5 mutation carriers
from BHC cases due to mutations in NKX2-1.
First, although both conditions can have extraneu-
ral involvement, NKX2-1 carriers often present with
pulmonary symptoms or evidence of endocrine de-
fects,21 whereas cardiac heart failure has been observed
in some affected individuals from the original FDFM
pedigree.11 ADCY5 overexpression has also been
shown to lead to cardiomyopathy in a mouse model.22
Second, the clinical progression between the 2 dis-
orders seems to be different. BHC cases secondary to
NKX2-1 mutations tend to remain relatively mildly
affected and often improve after childhood,21 while
we show here that ADCY5 mutation carriers may
present significant progression of symptoms, at least
until adult age. This difference in the clinical progres-
sion is nicely mirrored by the brain transcriptome
data. The analysis and comparison of ADCY5 and
NKX2-1 mRNA regional brain expression showed
that, although both genes are most highly expressed
in the adult striatum, ADCY5 levels progressively
increase during brain developmentwhereasNKX2-1 lev-
els show an opposite trend.
Third, prominent dystonic posturing is present in
the most severely affected cases with ADCY5mutations
and may dominate the clinical picture as the disease
progresses (video 1, section 1B). Mild dystonic features
can also be observed in some NKX2-1 cases,23,24 but
they are generally not as severe as we observed in
ADCY5 mutation carriers. Lastly, ADCY5-related dys-
kinesias are dramatically worsened by action, excite-
ment, or stress. This feature likely reflects the
biological role of adenyl cyclase 5. This enzyme cata-
lyzes the formation of cAMP (cyclic adenosine mono-
phosphate) upon b-adrenergic receptor stimulation via
G proteins in striatal cells, and pathogenic mutations
seem to increase the cyclase activity.16
Our study demonstrates that ADCY5 mutations
are responsible for familial and sporadic BHC and
further delineates the phenotype associated with
ADCY5 mutations. A diagnosis of ADCY5-related
disorder should be suspected when evaluating pa-
tients with a BHC-like presentation, regardless of
the presence of facial myokymia. Differences in the
clinical presentation may be attributed to distinct
molecular effects of different mutations, although
somatic mosaicism may explain intrafamilial pheno-
typic variability, as shown in family 1. We also sug-
gest that the term FDMD should not be used to refer
to ADCY5-related movement disorder because myo-
kymia may often not be part of the phenotype.
Given the possible reported association of ADCY5
mutations with cardiac involvement, it will be funda-
mental to closely follow up ADCY5 mutation carriers
in order to prevent or adequately treat potential car-
diac complications.
We confirm the usefulness of WES in the molecu-
lar diagnosis of rare and genetically heterogeneous
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movement disorders, such as BHC. WES should be
considered in the diagnostic workup of BHC after
the exclusion of acquired causes in sporadic cases and
mutations in the genes most frequently associated with
choreic syndromes.25 In particular, repeat expansions
(e.g., Huntington disease, SCA17 [spinocerebellar
ataxia 17], DRPLA [dentatorubral-pallidoluysian atro-
phy]) should be ruled out before performing WES
because these mutations are not easily detected with
this technology.
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